Valemetostat (DS-3201) tosylate, a first-in-class EZH1/2 dual inhibitor with IC 50 values In VitroValemetostat tosylate (1-1000 nM) strongly and specifically inhibits EZH1 and EZH2 with IC 50 values In VivoValemetostat tosylate (0.01 mg/g; i.p.; once) prevents the changes of H3K27me3 after exercise training. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male C57BL/6J mice with chronic and acute running exercise or without exercise Dosage: 0.01 mg/g Administration: Intraperitoneal injection; 0.01 mg/g; 30 min before the start of running exercise Result: Significantly increased the level of H3K27me3 , slightly decresed EZH1 level , upregulated the EZH2 level and increased the level of phosphorylated AMPK after exercise. Repressed myonuclear H3K27me3 accumulation during training and caused a failure of adaptive changes.Form:SolidIC50& Target:EZH1. Specification: 0.98 Molecular Formula: C33H42ClN3O7S Molecular Weight: 660.22 PubChem CID: 126482037 Isomeric SMILES: CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC(=C(C(=O)N1)CNC(=O)C2=CC(=C3C(=C2C)O[C@@](O3)(C)C4CCC(CC4)N(C)C)Cl)C
- UPC:
- 51182202
- Condition:
- New
- Availability:
- 8-12 weeks
- Weight:
- 1.06 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- V651952-25mg
- CAS:
- 1809336-93-3
- Product Size:
- 25mg
